NCT07374068Active, not recruiting
Prognostic Model of Elderly Hodgkin Lymphoma in China
Clinical Characteristics and Prognostic Model Analysis of Elderly Patients With Hodgkin Lymphoma in China
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
This multicenter observational cohort study is based on a patient registry designed to systematically collect uniform real-world clinical data from elderly patients with Hodgkin lymphoma (HL) in China. The registry captures demographic characteristics, disease features, laboratory parameters, treatment patterns, and longitudinal survival outcomes to support predefined scientific objectives. The primary analysis uses retrospectively collected registry data, with prospectively accrued data incorporated for external validation of a prognostic prediction model. This registry-based study aims to improve risk stratification and inform individualized clinical decision-making for elderly patients with HL in routine clinical practice.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 16 Dec 2025
- Start date
- 9 Dec 2025
- Primary completion date
- Dec 2028
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT07374068
What you commit to
- Study type: Observational
- Planned participants: 400
- From 9 Dec 2025 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of other malignant tumors
Other
- Severe hepatic or renal dysfunction (Child-Pugh class C or estimated glomerular filtration rate \<30 mL/min)
- Missing more than 20% of required clinical data
Who the study is looking for
- Age ≥60 years
- Histologically confirmed Hodgkin lymphoma, including classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma
- Treatment-naïve patients who have not received prior anti-Hodgkin lymphoma therapy
- Availability of complete clinical, pathological, and follow-up data
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Cancer Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.